What are the immunologically active components of Bacille Calmette-Guérin in therapy of superficial bladder cancer?
Alexandre R. Zlotta(University of Toronto), Kris Huygen(Institut Scientifique de Santé Publique), Liliane Schandené(Erasmus Hospital), Michel de Cock(Erasmus Hospital), Kamille Palfliet, Fabienne Jurion, Olivier Denis(Université Libre de Bruxelles), Pascal Lefèvre, Jean Content, Mamadou Daffé(Centre National de la Recherche Scientifique), Claude C. Schulman(Université Libre de Bruxelles), Jean‐Paul Van Vooren(Université Libre de Bruxelles), Jacques Simon(Institut Pasteur), Paul Vandenbussche, Jacqueline De Bruyn, Annie Drowart(Centre Hospitalier Universitaire Brugmann)
International Journal of Cancer
January 1, 2000
Cited by 65
Related Papers
Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes
|European Urology|2015|688
Immunogenicity and protective efficacy of a tuberculosis DNA vaccine
|Nature Medicine|1996|632
Newborns Develop a Th1-Type Immune Response to <i>Mycobacterium bovis</i> Bacillus Calmette-Guerin Vaccination
|The Journal of Immunology|1999|405